Levels of Protein, MCJ, May Predict Chemo Resistance and Relapse Risk in Breast Cancer Patients

Levels of Protein, MCJ, May Predict Chemo Resistance and Relapse Risk in Breast Cancer Patients
Breast cancer patients with low expression of a specific protein, methylation-controlled J protein (MCJ), may be resistant to chemotherapy treatments and at high risk of relapse, according to a retrospective study that included people with triple-negative breast cancer and an analysis of mice mammary tumors. The findings also indicate that MCJ may be a useful biomarker in predicting chemotherapy-resistant or recurrent tumors, and a potential therapeutic target for breast cancer treatment. The study, “Deficiency of mitochondrial modulator MCJ promotes chemoresistance in breast cancer,” was published in JCI Insight. Chemotherapy remains one of the most effective therapeutic strategies for the treatment of breast cancer, although the number of patients who don’t respond to it, or relapse despite it, is considerable. This treatment is especially crucial for people with triple-negative breast cancer, defined by the lack of estrogen and progesterone receptors and the human epidermal growth factor receptor 2 (HER2). These patients, dependent on chemotherapy treatment, have poor prognoses due to the inherent resistance of their tumors to chemotherapy drugs. They also present an increased risk of recurrence. As such, understanding the underlying mechanisms of drug resistance is essential to improved tumor treatment and patient survival. Researchers focused on methylation-controlled J protein (MCJ), a negative regulator of mitochondria
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.